FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Corcept Plans Resubmission of Cushings NDA

Corcept Therapeutics plans to resubmit its NDA for relacorilant as a treatment for patients with Cushings syndrome, following additional analyses requ...

latest-news-card-1
Human Drugs

AbbVies NDA for Dendritic Cell Neoplasms Approved

FDA approves an AbbVie NDA for Decnupaz (pivekimab sunirine-pvzy) and its use in treating adults with blastic plasmacytoid dendritic cell neoplasm.

latest-news-card-1
Human Drugs

FDA-483 Response Can Influence Future Agency Action: Post

NSF consultants report on a webinar discussing the best practices in responding to inspection observations in a form FDA-483.

latest-news-card-1

Seismic Loper Bright Impact Not Yet Seen: Attorneys

A Yale Journal on Regulation article from the Yale Law School Solomon Center for Health Law & Policy examines how the Supreme Courts Loper Bright deci...

latest-news-card-1
Human Drugs

Alchymars ICM SM Inspection Issues

FDA warns Indias Alchymars ICM SM Private Limited about CGMP deviations in its production of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

CGMP Issues at Japans Sato Pharmaceutical Co.

FDA warns Japans Sato Pharmaceutical Co. about CGMP violations in its production of finished over-the-counter drugs.

latest-news-card-1
Human Drugs

U.S. Urges High Court Rejection of Compounding Case

The U.S. government urges the Supreme Court to reject an appeal by a Texas compounding pharmacy in a closely watched case over whether federal drug la...

latest-news-card-1
Human Drugs

Outlook Wins FDA Appeal After 3 Complete Responses

Outlook Therapeutics wins an appeal with FDA over its BLA for ONS-5010/Lytenava (bevacizumab-vikg), clearing a potential path toward U.S. approval of ...

latest-news-card-1
Human Drugs

Intas Pharma Facility in India Hit With Form-483

FDA investigators cite major quality control and data integrity concerns at an Indian manufacturing facility operated by Intas Pharmaceuticals.

latest-news-card-1
Human Drugs

Dyne Files BLA for Duchenne Muscular Dystrophy Therapy

Dyne Therapeutics submits a BLA that seeks accelerated approval for its experimental Duchenne muscular dystrophy therapy z-rostudirsen.